PursueCare, a company that provides personalized virtual addiction treatment, announced the re-release of FDA-cleared RESET and RESET-O, prescription digital therapeutics (PDTs) for substance use disorder and opioid use disorder, respectively.
RESET and RESET-O were initially developed and commercialized by Pear Therapeutics, which filed for Chapter 11 bankruptcy last year. PursueCare acquired...
Tech-enabled sleep health company Nox Health was the highest bidder for Pear Therapeutics' Somryst assets at an auction last month that followed the prescription digital therapeutic company's bankruptcy in April.
Nox bid $3.9 million for Pear's FDA-cleared prescription digital therapeutic Somryst, which uses cognitive behavioral therapy for insomnia to train the brain and body to sleep.
Sigurjon...
Editor's note: This story has been updated with additional information on Pear's financial state.
The assets of prescription digital therapeutics maker Pear Therapeutics have been broken up and sold at auction for $6.05 million after the company filed for bankruptcy in April.
According to the court filing, Pear's assets were split between four bidders: Digital therapeutics company Click...
Editor's note: This story has been updated with additional information from a filing with the Securities and Exchange Commission.
Pear Therapeutics, maker of prescription digital therapeutics, announced today that it has filed for Chapter 11 bankruptcy and is seeking a sale of its business or assets.
The company will continue its scaled-down operations during Chapter 11 as it seeks a sale, and...
Prescription digital therapeutics company Pear Therapeutics is exploring "strategic alternatives," including a possible company sale, merger or acquisition.
In a press release, the company said it hired a financial advisor to look into actions that could "maximize shareholder value." That includes a potential sale, M&A, divestiture of assets, licensing or other strategic transactions. It may...
Pear Therapeutics' reSET and reSET-O prescription digital therapeutics are available to Florida's five million Medicaid patients via its Preferred Drug List as of this month.
Pear's reSET, a mobile application used to help treat substance abuse, received FDA De Novo clearance in 2017. The Boston-based company's reSET-O, used for opioid use disorder, received 510(k) clearance in 2018.
"The unmet...
Spero Health's 99 outpatient substance abuse centers will now have access to Pear Therapeutics' reSET and reSET-O prescription digital therapeutics to help treat individuals with substance use disorder and opioid use disorder.
The integrated healthcare services company previously used Pear's prescription digital therapeutics in 14 Kentucky locations. Thanks to the expanded partnership, Spero will...
Leaders in the digital health space told MobiHealthNews their predictions about investors' priorities in the coming year and what companies will need to watch out for.
Following 2021's expansive investments and the decrease in funding in 2022, alongside significant layoffs, stakeholders expect funders to be more selective in 2023 – scrutinizing companies' business models and considering whether...
MobiHealthNews spoke with several digital health stakeholders about 2022's funding environment and how it affected digital health startups.
Investments in 2022 decreased drastically compared to the swells of financial capital raised in 2021, and that lack of funding forced companies to rethink their business models.
Read digital health execs' insights on how this year's decreased funding forced...
As 2022 comes to a close, MobiHealthNews asked executives from across the digital health industry about their biggest takeaways from the year.
Check out their insights below on topics ranging from improving health equity to the continued use of virtual healthcare, especially for behavioral and mental health.
Chris Brickler, cofounder and CEO of MyndVR
"It's important not to get comfortable. In...
